We are live on ! Find out more
ASMB icon

Assembly Biosciences

106 hedge funds and large institutions have $286M invested in Assembly Biosciences in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 42 increasing their positions, 20 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

45,071% more call options, than puts

Call options by funds: $7.68M | Put options by funds: $17K

110% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 20

21% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 24

3% more funds holding

Funds holding: 103106 (+3)

0.33% less ownership

Funds ownership: 7.21%6.88% (-0.33%)

34% less capital invested

Capital invested by funds: $435M → $286M (-$149M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
106
Holders Change
+3
Holders Change %
+2.91%
% of All Funds
2.3%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
29
Increased
42
Reduced
20
Closed
24
Calls
$7.68M
Puts
$17K
Net Calls
+$7.66M
Net Calls Change
+$4.55M
Name Holding Trade Value Shares
Change
Change in
Stake
PM
26
Prosight Management
Texas
$2.7M -$1.81M -9,534 -36%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$2.34M +$2.75M +14,473 New
Fidelity Investments
28
Fidelity Investments
Massachusetts
$2.27M -$4.39M -23,108 -62%
ACP
29
Acuta Capital Partners
California
$2.13M -$9.54M -50,208 -79%
CM
30
Caption Management
Oklahoma
$2.07M +$2.43M +12,792 New
Two Sigma Investments
31
Two Sigma Investments
New York
$2.03M +$772K +4,059 +48%
Prudential Financial
32
Prudential Financial
New Jersey
$1.98M -$139K -733 -6%
Renaissance Technologies
33
Renaissance Technologies
New York
$1.8M +$1.63M +8,575 +339%
Charles Schwab
34
Charles Schwab
California
$1.69M +$101K +529 +5%
CIA
35
Capital Impact Advisors
Massachusetts
$1.65M -$895K -4,707 -82%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.4M +$293K +1,541 +22%
Barclays
37
Barclays
United Kingdom
$1.38M +$1.49M +7,837 +1,198%
FCM
38
Farallon Capital Management
California
$1.35M
Assenagon Asset Management
39
Assenagon Asset Management
Luxembourg
$1.31M +$1.54M +8,102 New
BFM
40
Boothbay Fund Management
New York
$1.27M +$1.5M +7,868 New
Canada Pension Plan Investment Board
41
Canada Pension Plan Investment Board
Ontario, Canada
$921K +$1.08M +5,692 New
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$859K +$220K +1,157 +28%
Two Sigma Advisers
43
Two Sigma Advisers
New York
$769K +$903K +4,750 New
AA
44
ALPS Advisors
Colorado
$721K +$847K +4,456 New
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$716K +$841K +4,424 New
USAA
46
United Services Automobile Association
Texas
$705K +$7.22K +38 +0.9%
DCM
47
DAFNA Capital Management
California
$682K
PP
48
PDT Partners
New York
$595K +$699K +3,675 New
Swiss National Bank
49
Swiss National Bank
Switzerland
$576K +$50.6K +266 +8%
FI
50
Fosun International
China
$471K

ASMB Hedge Fund Activity: Q2 2019 in Review

106 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q2 2019, worth a combined $286M — down 34% from $435M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ASMB positions and 24 closed out — a net gain of 5 holders — while 42 added to existing stakes and 20 trimmed.

The largest buyer was Armistice Capital, adding an estimated $13.8M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $18.3M sold.

  • 106 institutional investors held Assembly Biosciences (ASMB) as of Q2 2019, up from 103 in Q1 2019.
  • Funds reported $286M of Assembly Biosciences stock for Q2 2019, down 34% quarter-over-quarter.
  • 29 funds opened new Assembly Biosciences positions in Q2 2019 and 24 closed out, a net change of +5 holders.
  • The largest Assembly Biosciences buyer in Q2 2019 was Armistice Capital, an estimated $13.8M added.
  • The largest Assembly Biosciences seller in Q2 2019 was EcoR1 Capital, an estimated $18.3M sold.

Based on aggregated 13F filings for Q2 2019.